Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404624 | 1.00 | NOS3 (0.47) | NOS3NOS1NOS2SMN1; SMN2KMT2A | |
| SCHEMBL398710 | 0.87 | MEN1 (0.63) | NOS3NOS1NOS2SMN1; SMN2KMT2A | |
| SCHEMBL398709 | 0.87 | MEN1 (0.63) | NOS3NOS1NOS2SMN1; SMN2KMT2A | |
| SCHEMBL4920333 | 0.87 | TDP1 (0.60) | MMP1MMP2MMP9LMNAHDAC4 | |
| SCHEMBL4920338 | 0.87 | TDP1 (0.60) | MMP1MMP2MMP9LMNAHDAC4 | |
| SCHEMBL401389 | 0.87 | TDP1 (0.60) | MMP1MMP2MMP9LMNAHDAC4 | |
| SCHEMBL401390 | 0.87 | TDP1 (0.60) | MMP1MMP2MMP9LMNAHDAC4 | |
| SCHEMBL10286708 | 0.85 | TAS1R3 (0.65) | SMN1; SMN2MMP1MMP2MMP9RAB9A | |
| SCHEMBL403899 | 0.85 | HDAC2 (0.60) | LMNAHDAC4HDAC1HDAC8TDP1 | |
| SCHEMBL403898 | 0.85 | HDAC2 (0.60) | LMNAHDAC4HDAC1HDAC8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | NOS3 2605/4885NOS1 1583/4885NOS2 2130/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | NOS3 2605/4885NOS1 1583/4885NOS2 2130/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | NOS3 2605/4885NOS1 1583/4885NOS2 2130/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | NOS3 2605/4885NOS1 1583/4885NOS2 2130/4885 |
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | NOS3 2605/4885NOS1 1583/4885NOS2 2130/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | NOS3 2605/4885NOS1 1583/4885NOS2 2130/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | NOS3 2605/4885NOS1 1583/4885NOS2 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.